Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rhinil-2: Low-dose IL-2 in Birch Pollen Allergy
NCT03776643Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2019
- Primary completion
- Aug 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in allergic rhinitis (AR), sponsored by Assistance publique - Hôpitaux de Paris. Started Feb 2019; status: completed.
02
Drugs
aldesleukin
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT03776643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03776643.